-
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24 Apr 2024 08:00 GMT
… biotech company specializing in the development and manufacture of biosimilar medicines … All three study treatments were given at … Simponi Aria® (golimumab). Golimumab is a monoclonal … Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. …
-
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24 Apr 2024 08:10 GMT
… biotech company specializing in the development and manufacture of biosimilar medicines … All three study treatments were given at … Simponi Aria® (golimumab). Golimumab is a monoclonal … Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. …
-
Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
20 Apr 2024 12:31 GMT
… eg infliximab and adalimumab, golimumab, vedolizumab, ustekinumab, … there are limited pharmaceuticals available, particularly for … whilst pill counts assess how many pills patients … their prescribed medication in improving treatment adherence in inflammatory …
-
Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval
19 Apr 2024 20:21 GMT
… in the treatment of immune mediated diseases.
FDA approval was … development program for the drug included data from 2 … savings, while providing additional treatment options for patients.
Alvotech … to develop biosimilars for golimumab (Simponi and Simponi Aria …
-
Inflammatory Bowel Diseases (IBD) Drugs market is projected to grow at a CAGR 6.2% by 2034: Visiongain
12 Apr 2024 15:32 GMT
… the pharmaceutical industry demonstrated … drug class in the treatment of Inflammatory Bowel Diseases (IBD). These biologic medications … Golimumab (Simponi), Certolizumab pegol (Cimzia), and Ustekinumab (Stelara). Biologic drugs … trials and drug promotions …
-
Tofacitinib Treatment Before Colectomy Carries Minimal Postoperative Complication Risk
11 Apr 2024 11:48 GMT
… study of patients with medically refractory UC who underwent … and golimumab), vedolizumab, and ustekinumab were considered active treatment. The … ) complications between the 4 treatment groups. For secondary outcomes, … , the class of drug did not influence the …
-
PFCD: Are Outcomes Better With Combined Medical-Surgical Tx?
28 Mar 2024 12:22 GMT
… infliximab, adalimumab, certolizumab pegol, or golimumab).
Co-primary outcomes were fistula … Gastroenterology and Hepatology, Department of Medicine, University of Ottawa, Ottawa, Ontario … /or honoraria from various pharmaceutical companies.
-
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
23 Mar 2024 05:15 GMT
… the EXAMINE trial, investigated alogliptin medication in individuals … remedies are being considered to treat COVID-19 including phage-vaccine … enhance treatment efficacy.
Drug repurposing and new drug development … virus infections. Pharmaceuticals. 2019;12:101 …
-
Nationwide Study Highlights Infection Risk Levels for PsA Patients on Different Treatments
20 Mar 2024 20:59 GMT
… individuals newly using various drugs, such research had … vital status, pharmacy-provided treatments, and eligibility for reimbursement … focus on new medication users defined as … at certolizumab pegol, adalimumab, golimumab, etanercept, and infliximab (TNFi …
-
Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome and Paradoxical Psoriasis with Secukinumab: A Case Report
05 Mar 2024 12:20 GMT
… As a result, methylprednisolone pills (16 mg, daily) … inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs … adalimumab, certolizumab pegol, golimumab, and etanercept, and … the treatment of SAPHO syndrome and medication recommendations. …